Plasticité phénotypique et génétique du cancer : Ch. Theillet/C. Sardet

Liste des Publications

Alexandre M, Jacot W [Therapeutic advances in HER2+ breast cancer]. Rev Prat. 2023;73(4):355-359.

Hurvitz S, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu J, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning J-W, Curigliano G, Perez-Garcia J, Kim S-B, Petry V, Huang C-S, Li W, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105-117. doi:10.1016/S0140-6736(22)02420-5

Mailliez A, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladieff L, Ferrero J-M, Petit T, Mouret-Reynier M, Eymard J-C, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Simon G, Jacot W, Delaloge S Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2023;152(5):921-931. doi:10.1002/ijc.34304

Alcaraz L, Mallavialle A, Mollevi C, Boissière-Michot F, Mansouri H, Simony-Lafontaine J, Laurent-Matha V, Chardès T, Jacot W, Turtoi A, Roger P, Guiu S, Liaudet-Coopman E SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity. Int J Cancer. 2023;152(6):1243-1258. doi:10.1002/ijc.34345

Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeulin T, Emile G, Ung M, Robert M, Desmoulins I, Jouannaud C, Uwer L, Marc Ferrero J, Mouret-Reynier M-A, Jacot W, Chevrot M, Delaloge S Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program. Oncologist. 2023;28(10):e867-e876. doi:10.1093/oncolo/oyad137

Grinda T, Antoine A, Jacot W, Cottu P-H, Frenel J-S, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret Reynier M-A, Levy C, Ferrero J-M, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Pérol D, Pistilli B, Delaloge S Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. Eur J Cancer. 2023;189. doi:10.1016/j.ejca.2023.05.023

Griguolo G, Aldegheri V, Bottosso M, Pittaro A, Caumo F, Guarascio M, Busato F, Miglietta F, Jacot W, Dieci M, Guarneri V Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients. Int J Cancer. 2023;153(6):1217-1226. doi:10.1002/ijc.34571

Bottosso M, Griguolo G, Sinoquet L, Guarascio M, Aldegheri V, Miglietta F, Vernaci G, Barbieri C, Girardi F, Jacot W, Guarneri V, Darlix A, Dieci M Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases. Br J Cancer. 2023;128(7):1286-1293. doi:10.1038/s41416-023-02153-w

Bourla C, Taoum C, Kanté S, Mourregot A, Rouanet P, Colombo P-E Port placement strategies and management of the robotic system during total colectomy or total coloproctectomy for cancer - A video vignette. Colorectal Dis. 2023;25(8):1733-1735. doi:10.1111/codi.16629

Glaviano A, Foo A, Lam H, Yap K, Jacot W, Jones R, Eng H, Nair M, Makvandi P, Geoerger B, Kulke M, Baird R, Prabhu J, Carbone D, Pecoraro C, Teh D, Sethi G, Cavalieri V, Lin K, Javidi-Sharifi N, Toska E, Davids M, Brown J, Diana P, Stebbing J, Fruman D, Kumar A PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. doi:10.1186/s12943-023-01827-6

Bidard F-C, Kiavue N, Jacot W, Bachelot T, Dureau S, Bourgeois H, Goncalves A, Brain E, Ladoire S, Dalenc F, Gligorov J, Teixeira L, Emile G, Ferrero J-M, Loirat D, Cabel L, Kadi A, Alix-Panabières C, Pierga J-Y Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. J Clin Oncol. 2023-11-06. doi:10.1200/JCO.23.00456

Quesada S, Thomas Q, Colombo P-E, Fiteni F Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?. Cancers (Basel). 2023;15(14):3556. doi:10.3390/cancers15143556

Campos-Mora M, Jacot W, Garcin G, Depondt M-L, Constantinides M, Alexia C, Villalba M NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells. Front Immunol. 2023;14. doi:10.3389/fimmu.2023.1199594

Houvenaeghel G, Cohen M, Martino M, Reyal F, Classe J-M, Chauvet M-P, Colombo P-E, Heinemann M, Jouve E, Gimbergues P, Azuar A-S, Coutant C, de Nonneville A Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery. Cancers (Basel). 2023;15(18):4567. doi:10.3390/cancers15184567

Hutchinson K, Chen J, Savage H, Stout T, Schimmoller F, Cortés J, Dent S, Harbeck N, Jacot W, Krop I, Trabucco S, Sivakumar S, Sokol E, Wilson T Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers. Genome Med. 2023;15(1):28. doi:10.1186/s13073-023-01181-8

Sinoquet L, Jacot W, Quantin X, Alix-Panabières C Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. Clin Chem. 2023;69(1):23-40. doi:10.1093/clinchem/hvac166

Arquillière J, Dubois A, Rullier E, Rouanet P, Denost Q, Celerier B, Pezet D, Passot G, Aboukassem A, Colombo P, Mourregot A, Carrere S, Vaudoyer D, Gourgou S, Gauthier L, Cotte E Learning curve for robotic-assisted total mesorectal excision: a multicentre, prospective study. Colorectal Dis. 2023;25(9):1863-1877. doi:10.1111/codi.16695

Lazaratos A-M, Maritan S, Quaiattini A, Ratosa I, Ferraro E, Griguolo G, Guarneri V, Pellerino A, Hofer S, Jacot W, Stemmler H-J, van den Broek M, Dobnikar N, Panet F, Lahijanian Z, Morikawa A, Seidman A, Soffietti R, Panasci L, Petrecca K, Rose A, Bouganim N, Dankner M Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Breast. 2023;69. doi:10.1016/j.breast.2023.04.008

Fabbro M, Jacot W, Jarlier M, Guiu S, D'Hondt V, Champoiral P, Janiszewski C, Nicklès I Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study. Cancer Rep (Hoboken). 2023;6(1):e1732. doi:10.1002/cnr2.1732

Garcia-Prada C, Carmes L, Atis S, Parach A, Bertolet A, Jarlier M, Poty S, Garcia D, Shin W-G, Schuemann J, Tillement O, Lux F, Constanzo J, Pouget J-P Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy. J Nucl Med. 2023-10-19. doi:10.2967/jnumed.123.265418

Tarantino P, Viale G, Press M, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein H, Carey L, Denkert C, Jacot W, Koutras A, Lebeau A, Loibl S, Modi S, Mosele M, Provenzano E, Pruneri G, Reis-Filho J, Rojo F, Salgado R, Schmid P, Schnitt S, Tolaney S, Trapani D, Vincent-Salomon A, Wolff A, Pentheroudakis G, Curigliano G ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34(8):645-659. doi:10.1016/j.annonc.2023.05.008

Chen J, Jacot W, Cortés J, Krop I, Dent S, Harbeck N, De Laurentiis M, Im Y-H, Stout T, Schimmoller F, Savage H, Hutchinson K, Wilson T ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Mol Oncol. 2023;17(10):2000-2016. doi:10.1002/1878-0261.13416

Frenel J-S, Lusque A, Delaloge S, Ferrero J-M, Bachelot T, Desmoulins I, Levy C, Eymard J-C, Patsouris A, Reynier M, Thery M-C, Petit T, Cabel L, Uwer L, Debled M, Chevrot M, Mailliez A, Jacot W, de La Motte Rouge T Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. Br J Cancer. 2023;128(11):2072-2080. doi:10.1038/s41416-023-02248-4

Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo P-E, Classe J-M, Chevrier M, Joly F, Floquet A, Sabatier R, Barranger E, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. Int J Gynecol Cancer. 2023;33(4):577-584. doi:10.1136/ijgc-2022-003993

Vendrell J, Ban I, Solassol I, Audran P, Cabello-Aguilar S, Topart D, Lindet-Bourgeois C, Colombo P-E, Legouffe E, D'Hondt V, Fabbro M, Solassol J Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. Int J Mol Sci. 2023;24(18):14181. doi:10.3390/ijms241814181

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés